Comparing GH Research (NASDAQ:GHRS) and Gyre Therapeutics (NASDAQ:GYRE)

Gyre Therapeutics (NASDAQ:GYRE) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gyre Therapeutics and GH Research, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2	0	2	0	2.00
GH Research	1	1	9	0	2.73

Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 177.32%. GH Research has a consensus price target of $40.38, indicating a potential upside of 71.01%. Given Gyre Therapeutics’ higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than GH Research.

Earnings and Valuation

This table compares Gyre Therapeutics and GH Research”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$117.05 million	5.08	$5.03 million	($0.09)	-68.11
GH Research	N/A	N/A	-$48.26 million	($0.92)	-25.66

Gyre Therapeutics has higher revenue and earnings than GH Research. Gyre Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gyre Therapeutics and GH Research’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
GH Research	N/A	-19.36%	-18.73%

Institutional & Insider Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Gyre Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Summary

Gyre Therapeutics beats GH Research on 8 of the 13 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.